Stanford scientists have discovered that blocking an immune receptor signal can lead to increased fat uptake and weight reduction in patients suffering from obesity and associated diseases.
Stanford inventors in the Katrin Svensson laboratory have identified the protein Isthmin-1 (ISM1) as a treatment for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).